Latest Temozolomide Stories
-- Increases Total Number of DelMar Patents Covering VAL-083 to Three US Patents and One International Patent -- VANCOUVER, British Columbia and MENLO PARK, Calif., Jan.
-- First Observation of Dose Limiting Toxicity Signals VAL-083's Potential Advancement Toward Registration Directed Clinical Trials in Refractory Glioblastoma -- VANCOUVER, British Columbia
Aldoxorubicin Shows a Complete Response, Tumor Shrinkage, Prolonged Stable Disease, and Favorable Tolerability in Patients LOS ANGELES, Jan.
BUFFALO, N.Y., Dec.
PORTLAND, Oregon, December 2, 2014 /PRNewswire/ -- GBI Research, the leading business intelligence provider, has released its latest research, "Glioblastoma Multiforme
Based on the results of the trial's pre-specified interim analysis all control patients in the EF-14 phase III trial will be offered the opportunity to cross over to receive Tumor Treating Fields
Planned interim analysis demonstrates the EF-14 Phase III trial met its endpoints of progression-free survival and overall survival ST. HELIER, Jersey, Dec.
Data Presented at the 19th Annual Society for Neuro-Oncology Meeting Demonstrate VAL-083 Superiority to Temozolomide in Key Preclinical Models VANCOUVER, British Columbia, MENLO PARK, Calif.,
Data presented today as a late-breaking abstract at the Society for Neuro-Oncology 2014 Annual Meeting in Miami demonstrated the EF-14 trial met its primary endpoint of progression-free survival and
- An imitative word; an onomatopoetic word.